Research Article
Prestroke Metformin Use on the 1-Year Prognosis of Intracerebral Hemorrhage Patients with Type 2 Diabetes
Table 2
The discharge and follow-up information of those included ICH patients stratified according to MET usea.
| | ALL | MET use | | MET (+) | MET (--) |
| | Discharge, | 730 | 281 | 449 | | Died | 58 (7.9 [6.0-9.9]) | 18 (6.4 [3.5-9.3]) | 40 (8.9 [6.3-11.5]) | | Survivors | 672 (92.1 [90.1-94.0]). | 263 (93.6 [90.7-96.5]) | 409 (91.1 [88.5-93.7]) | | mRS of survivors | 2 (1-4) | 2 (1-4) | 2 (1-4) | | Discharge against medical advice | 83 (11.4 [9.1-13.7]) | 30 (10.7 [7.1-14.3]) | 53 (11.8 [8.8-14.8]) | | Follow-up at 1 year after admission | 672 | 263 | 409 | | Lost follow-up | 73 (10.9) | 22 (8.4) | 51 (12.5) | | Finished follow-up | 599 (90.1) | 241 (91.6) | 358 (87.5) | | Died | 108 (18.0 [15.0-21.1]) | 37 (14.1 [9.9-18.3] | 71 (17.4 [13.7-21.0] | | Survivors | 491 (82.0) | 204 (85.9) | 287 (82.6) | | mRS 0 | 139 (28.3) | 57 (27.9) | 82 (28.6) | | mRS 1 | 99 (20.2) | 42 (20.6) | 57 (19.9) | | mRS 2 | 97 (19.8) | 47 (23.0) | 50 (17.4) | | mRS 3 | 70 (14.3) | 23 (11.3) | 47 (16.4) | | mRS 4 | 58 (11.8) | 23 (11.3) | 35 (12.2) | | mRS 5 | 28 (5.7) | 12 (5.9) | 16 (5.6) | | Disability ratea | 156 (31.8 [27.7-35.9]) | 58 (28.4 [22.2-34.6]) | 98 (34.1 [28.7-39.6] | | Recurrence rate among survivors | 30 (6.1 [4.0-8.2]) | 13 (6.4 [3.0-9.7]) | 17 (5.9 [3.2-8.7]) |
|
|
Abbreviation: mRS: Modified Rankin Scale; CI: confidence interval; MET: metformin. aDisability event was defined as an mRS of 3 to 5 points.
|
